The use of bromocriptine in addition to standard heart failure therapy in the attempt to block the detrimental effect of cleaved prolactin has been shown to increase the rate of LV recovery and reduce mortality in two randomized, open‐label trials conducted in Africa.24, 25 A recent randomized trial from Germany evaluating 1‐week vs 8 weeks of bromocriptine therapy in 63 women with PPCM found similar improvement in LVEF.26 The study, however, was limited by the lack of a control group not receiving bromocriptine. This evidence concerns the gene PRL and heart failure.